TY - JOUR
T1 - Addressing the challenges of polygenic scores in human genetic research
AU - Novembre, John
AU - Stein, Catherine
AU - Asgari, Samira
AU - Gonzaga-Jauregui, Claudia
AU - Landstrom, Andrew
AU - Lemke, Amy
AU - Li, Jun
AU - Mighton, Chloe
AU - Taylor, Matthew
AU - Tishkoff, Sarah
N1 - Publisher Copyright:
© 2022
PY - 2022/12/1
Y1 - 2022/12/1
N2 - The genotyping of millions of human samples has made it possible to evaluate variants across the human genome for their possible association with risks for numerous diseases and other traits by using genome-wide association studies (GWASs). The associations between phenotype and genotype found in GWASs make possible the construction of polygenic scores (PGSs), which aim to predict a trait or disease outcome in an individual on the basis of their genotype (in the disease case, the term polygenic risk score [PRS] is often used). PGSs have shown promise for studying the biology of complex traits and as a tool for evaluating individual disease risks in clinical settings. Although the quantity and quality of data to compute PGSs are increasing, challenges remain in the technical aspects of developing PGSs and in the ethical and social issues that might arise from their use. This ASHG Guidance emphasizes three major themes for researchers working with or interested in the application of PGSs in their own research: (1) developing diverse research cohorts; (2) fostering robustness in the development, application, and interpretation of PGSs; and (3) improving the communication of PGS results and their implications to broad audiences.
AB - The genotyping of millions of human samples has made it possible to evaluate variants across the human genome for their possible association with risks for numerous diseases and other traits by using genome-wide association studies (GWASs). The associations between phenotype and genotype found in GWASs make possible the construction of polygenic scores (PGSs), which aim to predict a trait or disease outcome in an individual on the basis of their genotype (in the disease case, the term polygenic risk score [PRS] is often used). PGSs have shown promise for studying the biology of complex traits and as a tool for evaluating individual disease risks in clinical settings. Although the quantity and quality of data to compute PGSs are increasing, challenges remain in the technical aspects of developing PGSs and in the ethical and social issues that might arise from their use. This ASHG Guidance emphasizes three major themes for researchers working with or interested in the application of PGSs in their own research: (1) developing diverse research cohorts; (2) fostering robustness in the development, application, and interpretation of PGSs; and (3) improving the communication of PGS results and their implications to broad audiences.
UR - http://www.scopus.com/inward/record.url?scp=85143305002&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2022.10.012
DO - 10.1016/j.ajhg.2022.10.012
M3 - Review article
C2 - 36459976
AN - SCOPUS:85143305002
SN - 0002-9297
VL - 109
SP - 2095
EP - 2100
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 12
ER -